July 26, 2024 (Globalinvestorideas.com Newswire) Globalinvestorideas.com, a go-to platform for big investing ideas, including biotech stocks reports on trading for Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases.
The stock is trading at $6.74, gaining $3.44, up 104.25%, making the NASDAQ top percentage gainers list. The stock had a day’s high of $9.40 on volume of over 30 Million shares.
Windtree Therapeutics today announced an update of istaroxime in both clinical and business development. Istaroxime is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function. It has been studied in three positive Phase 2 trials enrolling patients with acute heart failure (AHF) and early cardiogenic shock.
In line with previous guidance, the Company expects its Phase 2 SEISMiC Extension Study in SCAI Stage B early cardiogenic shock patients to complete enrollment in the next several weeks and report topline data by the end of this quarter. Building upon the positive SEISMiC study results, the Extension Study is focused on dose optimization and additional characterization of SERCA2a effects for Phase 3 planning and is expected to enroll up to 30 patients. The study of hospitalized patients with early cardiogenic shock (SCAI Stage B) due to AHF evaluates two-dose regimens of istaroxime compared to placebo. Patients will receive infusions of istaroxime for up to 60 hours, with one group receiving a decreasing istaroxime dose over time and the second group receiving a consistent istaroxime dose. This study will extend the dosing duration compared to the previous positive SEISMiC study, in which study treatment was limited to 24 hours. The Company believes extending the dosing duration of istaroxime has the potential to provide additional benefit and, along with dose titration, is an important factor in determining the optimal dosing regimen to study in late-stage trials. The study is also collecting detailed information related to heart function, particularly associated with the SERCA2a mechanism of action. Istaroxime has not been associated with an increase in cardiac arrhythmias, which the Company believes is a potentially important differentiating characteristic compared to currently used inotropes and vasopressors.
Further, the Extension Study is measuring the effects of istaroxime on blood pressure and cardiac function with the two dosing regimens similar to the improvements seen in the previous SEISMiC study.
The Company is also progressing the start-up of a parallel study in more severe, SCAI Stage C cardiogenic shock patients. SCAI stage C is a more severely ill population than was previously studied in the SEISMiC study. SEISMiC C data will be reviewed after enrollment of up to 20 patients with SCAI Stage C cardiogenic shock due to acute decompensated heart failure. It will be a placebo controlled, double-blinded study with istaroxime being added to current standard of care using inotropes or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours followed by withdrawal of the standard of care therapies. The primary endpoint is assessment of systolic blood pressure (SBP) area under the curve over the first 6 hours of treatment. Other key study measurements include: SBP changes at specified timepoints, the vasopressor-inotrope score, progression to SCAI Stage D or E cardiogenic shock, time to treatment failure, arrhythmia assessments, days alive and out of the hospital through day 30, physiologic measures (e.g., cardiac index) and length of stay in the ICU and hospital. The execution of this study will depend on the Company’s ability to obtain adequate resources for its completion.
Finally, the Company announced in January 2024 it entered into a license agreement with Lee’s Pharmaceutical (HK) Limited (“Lee’s”) for the development and commercialization of istaroxime in Greater China, including for AHF and cardiogenic shock. In addition to istaroxime, the agreement also licenses Windtree’s preclinical next-generation dual mechanism SERCA2a activators, and rostafuroxin, a Phase 2 product candidate for hypertension associated with specific genotypes. The agreement provides Windtree potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for products in the licensed territory. We expect to provide a development update on Lee’s program later this year. Lee’s is focused on progressing acute heart failure in Greater China while Windtree executes a global cardiogenic shock program.
Recent news
https://finance.yahoo.com/news/windtree-therapeutics-provides-istaroxime-clinical-120000427.html
Research more biotech stocks with Investorideas.com free stock directory https://www.investorideas.com/BIS/Stock_List.asp
About Investorideas.com – Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.
Disclaimer
Global Investor Ideas is part of the Investorideas.com content umbrella and is owned by Econ Corporate Services Inc. For Investorideas disclosure and disclaimer please visit the site directly
Disclaimer/Disclosure: GlobalInvestorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by GlobalInvestorideas and investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. If we are not the source for content but just a publisher , please contact the source of all content for questions and info. We are not responsible for third party content.